ArticleScientific reports2020
The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990-2017.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.BMC nephrology · 2025Pooled it
- Long-Term or Recurrent Antibiotic Use During Childhood or Adolescence and the Risk of Kidney Cancer: A Cohort Study.Cancer medicine · 2026Article
- Trends and health inequalities in the global burden of kidney cancer from 1990 to 2021, with projections to 2040.Medicine · 2026Article
- Global patterns and trends in kidney cancer incidence and mortality.International journal of cancer · 2026Article
- Epidemiological Trends and Burden of Adult Kidney Cancer in Saudi Arabia: A 42-Year Retrospective Analysis (1982-2023).Cancer reports (Hoboken, N.J.) · 2026Observational
- Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan.Frontiers in public health · 2026Article
- Patients' knowledge, attitudes, preferences regarding kidney cancer screening, and factors influencing participation intentions: a qualitative study.Frontiers in oncology · 2026Article
- Global, Regional, National and HDI-Stratified Burdens of Intraocular Foreign Bodies from 1990 to 2021: A Trend Analysis.Risk management and healthcare policy · 2026Article
- Long-term environmental background radiation is associated with urinary tract cancer incidence: A population-based study from Finland.Cancer epidemiology · 2025Article
- Global burden of kidney cancer attributable to smoking: A systematic analysis of the 1990-2021 global burden of disease study.Preventive medicine reports · 2025Article
- Rising incidence and clinical impact of kidney cancer in China and worldwide: a call for targeted prevention, early diagnosis, and equitable treatment.Translational andrology and urology · 2025Article
- Article
- Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical-biochemical parameters and patient outcome.International journal of cancer · 2025Article
- Global Burden of Kidney Cancer Attributable to High Body Mass Index in Adults Aged 60 and Older from 1990 to 2021 and Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study.Clinical epidemiology · 2025Article
- Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Microfluidics and molecular diagnostics in renal cell carcinoma: advances, challenges, and future directions.Frontiers in oncology · 2025Review
- Cumulative Burden of Fatty Liver and Kidney Cancer in Young Men: A National Population-Based Study.Journal of clinical medicine · 2024Article
- Trends in the Mortality Rate of Major Kidney Diseases - China, 2014-2021.China CDC weekly · 2024Article
- Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2024Article
- Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).Japanese journal of clinical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney cancer globally accounts for more than 131,000 deaths each year and has been found to place a large economic burden on society. However, there are no recent articles on the burden of kidney cancer across the world. The aim of this study was to present a status report on the incidence, mortality and disability-adjusted life years (DALYs) associated with kidney cancer in 195 countries, from 1990 to 2017. Vital registration and cancer registry data (total of 23,660 site-years) were used to generate the estimates. Mortality was estimated first and the incidence and DALYs were calculated based on the estimated mortality values. All estimates were presented as counts and age-standardised rates per 100,000 population. The estimated rates were calculated by age, sex and according to the Socio-Demographic Index (SDI). In 2017, kidney cancer accounted for 393.0 thousand (95% UI: 371.0-404.6) incident cases, 138.5 thousand (95% UI: 128.7-142.5) deaths and 3.3 million (95% UI: 3.1-3.4) DALYs globally. The global age-standardised rates for the incidence, deaths and DALY were 4.9 (95% UI: 4.7-5.1), 1.7 (95% UI: 1.6-1.8) and 41.1 (95% UI: 38.7-42.5), respectively. Uruguay [15.8 (95% UI: 13.6-19.0)] and Bangladesh [1.5 (95% UI: 1.0-1.8)] had highest and lowest age-standardised incidence rates, respectively. The age-standardised death rates varied substantially from 0.47 (95% UI: 0.34-0.58) in Bangladesh to 5.6 (95% UI: 4.6-6.1) in the Czech Republic. Incidence and mortality rates were higher among males, than females, across all age groups, with the highest rates for both sexes being observed in the 95+ age group. Generally, positive associations were found between each country's age-standardised DALY rate and their corresponding SDI. The considerable burden of kidney cancer was attributable to high body mass index (18.5%) and smoking (16.6%) in both sexes. There are large inter-country differences in the burden of kidney cancer and it is generally higher in countries with a high SDI. The findings from this study provide much needed information for those in each country that are making health-related decisions about priority areas, resource allocation, and the effectiveness of prevention programmes. The results of our study also highlight the need for renewed efforts to reduce exposure to the kidney cancer risk factors and to improve the prevention and the early detection of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.